Diabetes awareness survey reveals alarming figures across the Middle East and Northern Africa regions

Novo NordiskIn the lead up to World Diabetes Day 2010 on 14 November Novo Nordisk and Ipsos Emirates Health conducted a survey in ten countries of the Middle East and Northern Africa (MENA) region: Algeria, Egypt, Iran, Iraq, Jordan, Lebanon, Morocco, Kingdom of Saudi Arabia (KSA), Tunisia and the United Arab Emirates (UAE).

The survey, which was carried out in October this year, assesses the level of awareness among the general population when it comes to causes, risks and complications of diabetes. It also looks into respondents' risk of developing diabetes. With over 3,000 interviews, the respondents were representative of the demographic and socio-economic profile in each country.

The survey shows that 41% of respondents are at risk of developing diabetes. Despite a high awareness level of the scale of the disease, only one in two respondents consider diabetes to be a severe or a very severe disease. Myths about diabetes also remain very common:

  • 31% of Algerian respondents believe that diabetes is contagious
  • Stress was ranked as a leading cause of diabetes across the region (39%)
  • Half of respondents (52%) declared that stroke cannot be caused by diabetes

"The results of the MENA diabetes awareness survey are striking. The need to further educate the general public about the risk factors, complications and the severity of the condition is very clear. We hope that the initiative will inspire authorities to tackle this issue. We believe that early detection of diabetes, prevention and education can make a real difference," said Lise Kingo, executive vice president and chief of staffs at Novo Nordisk.

Diabetes is sweeping the MENA region affecting an estimated 26.6 million people today, creating overwhelming demands on the region's healthcare systems and huge financial burdens on its governments. As alarming as this picture is, the number of people with diabetes is expected to double to 51.7 million people by 2030.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com.

Most Popular Now

AstraZeneca amends collaboration with Ironwood for…

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclo...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

FDA grants Fast Track designation for Farxiga in h…

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk ...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Educational campaign helps teens and their caregiv…

Teenagers face many challenges, and growing up with a chronic skin disease called atopic dermatitis (AD) can impact the ups and downs and transitions to young adulthood. ...

Gene-targeted cancer drugs, slow release overcome …

Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, prot...

Ian Read to retire as Executive Chairman of Pfizer…

Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to...

Novartis and Microsoft announce collaboration to t…

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science pa...

Study points to new drug target in fight against c…

Researchers have identified a potential new drug target in the fight against cancer. In a study this week in the Proceedings of the National Academy of Sciences, an inter...